Pfizer Launched Phase 3 Trial for Ibuzatrelvir, New Oral Antiviral for COVID-19 Treatment
Charlotte Allerton explains how ibuzatrelvir, a second-generation treatment, could reduce drug interactions and taste disturbances compared to PAXLOVID, offering a simplified approach for high-risk patients.